Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair...

Descripción completa

Detalles Bibliográficos
Autores principales: Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R., Hoimes, Christopher J., George, Daniel J., Armstrong, Andrew J., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://www.ncbi.nlm.nih.gov/pubmed/33115529
http://dx.doi.org/10.1186/s13045-020-00978-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://www.ncbi.nlm.nih.gov/pubmed/33115529
http://dx.doi.org/10.1186/s13045-020-00978-z

Ejemplares similares